• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gyre Therapeutics, Inc. - Common Stock (NQ:GYRE)

7.260 -0.080 (-1.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 133,218
Open 7.340
Bid (Size) 7.000 (300)
Ask (Size) 7.500 (2,000)
Prev. Close 7.340
Today's Range 7.050 - 7.470
52wk Range 5.440 - 9.420
Shares Outstanding 37,759,825
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
May 12, 2026
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
May 07, 2026
From Gyre Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+6.6%
+6.6%
1 Month
+20.0%
+20.0%
3 Month
+2.0%
+2.0%
6 Month
-8.3%
-8.3%
1 Year
-4.7%
-4.7%

More News

Read More
News headline image
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
May 04, 2026
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
March 17, 2026
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 12, 2026
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead ↗
March 02, 2026
Via Stocktwits
News headline image
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
January 05, 2026
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Inc (NASDAQ:GYRE) Reports Q3 2025 Earnings Beat Amid Revenue Miss and Lowered Guidance ↗
November 07, 2025
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 7, 2025 ↗
November 07, 2025
Via Benzinga
News headline image
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
November 07, 2025
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
October 15, 2025
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
October 14, 2025
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
October 10, 2025
Via Benzinga
News headline image
Elastic, Applied Digital, Eightco Holdings And Other Big Stocks Moving Higher On Friday ↗
October 10, 2025
Via Benzinga
News headline image
This Aptiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
October 10, 2025
Via Benzinga
BioMedNewsBreaks — Gyre Therapeutics (NASDAQ: GYRE) Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone
September 09, 2025
Via Investor Brand Network
News headline image
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 05, 2025
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker ↗
August 26, 2025
Via Benzinga
News headline image
This Actuate Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday ↗
August 26, 2025
Via Benzinga
News headline image
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
August 22, 2025
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
August 11, 2025
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
June 10, 2025
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 29, 2025
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday ↗
May 27, 2025
Via Benzinga
Topics Artificial Intelligence
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
May 23, 2025
Via Chartmill

Frequently Asked Questions

Is Gyre Therapeutics, Inc. - Common Stock publicly traded?
Yes, Gyre Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Gyre Therapeutics, Inc. - Common Stock trade on?
Gyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Gyre Therapeutics, Inc. - Common Stock?
The ticker symbol for Gyre Therapeutics, Inc. - Common Stock is GYRE on the Nasdaq Stock Market
What is the current price of Gyre Therapeutics, Inc. - Common Stock?
The current price of Gyre Therapeutics, Inc. - Common Stock is 7.260
When was Gyre Therapeutics, Inc. - Common Stock last traded?
The last trade of Gyre Therapeutics, Inc. - Common Stock was at 07/06/26 04:00 PM ET
What is the market capitalization of Gyre Therapeutics, Inc. - Common Stock?
The market capitalization of Gyre Therapeutics, Inc. - Common Stock is 274.14M
How many shares of Gyre Therapeutics, Inc. - Common Stock are outstanding?
Gyre Therapeutics, Inc. - Common Stock has 274M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap